<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943057</url>
  </required_header>
  <id_info>
    <org_study_id>R1226/32/2015</org_study_id>
    <nct_id>NCT02943057</nct_id>
  </id_info>
  <brief_title>Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis</brief_title>
  <official_title>Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore National Eye Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore National Eye Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either&#xD;
      uveitis or endotheliitis, will be started on 2% guttae ganciclovir, 1 drop 5 times a day for&#xD;
      6 weeks.&#xD;
&#xD;
      Following 6 weeks of continuous application of 2% guttae ganciclovir, patient will be&#xD;
      reviewed at the clinic within 3 hours following the last application of topical ganciclovir&#xD;
      and clinical features will be documented for activity assessment. An aqueous sample 0.2ml is&#xD;
      drawn. 0.1ml will be sent for RT-PCR for CMV viral load and another 0.1ml will be sent for&#xD;
      ganciclovir drug level by HPLC method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is non-randomised single armed prospective, cross-sectional, interventional clinical&#xD;
      study.&#xD;
&#xD;
      25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either&#xD;
      uveitis or endotheliitis, at the investigators clinic in Singapore National Eye Centre, who&#xD;
      have a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for CMV and have&#xD;
      not had any form of ganciclovir treatment in the past 1 month, will be recruited in the study&#xD;
      after taking an informed consent. This will also include the patients who have never been&#xD;
      treated with antiviral therapy and those with recurrent disease and have not had any form of&#xD;
      ganciclovir treatment for past 1 month.&#xD;
&#xD;
      The clinical features of the active disease will be recorded in the data collection sheet and&#xD;
      will include, documentation of the state of the cornea, KPs, AC cells, flare, flare meter&#xD;
      reading (where possible), central corneal thickness, Intra ocular pressure (IOP) and C:D&#xD;
      ratio.&#xD;
&#xD;
      All patients will be started on 2% guttae ganciclovir, 1 drop 5 times a day.&#xD;
&#xD;
      2% Guttae ganciclovir will be prepared from vials of ganciclovir powder for ganciclovir&#xD;
      intravenous infusion using aseptic method.&#xD;
&#xD;
      Following 6 weeks of continuous application of 2% guttae ganciclovir, patient will be&#xD;
      reviewed at the clinic within 3 hours following the last application of topical ganciclovir.&#xD;
&#xD;
        1. Clinical features mentioned above will be documented for activity assessment&#xD;
&#xD;
        2. Following irrigation of the conjunctival sac with 100ml of N/S to wash out any residual&#xD;
           drug, aseptic technique is practised before an aqueous sample 0.2ml is drawn. 0.1ml will&#xD;
           be sent for RT-PCR for CMV viral load and another 0.1ml will be sent for ganciclovir&#xD;
           drug level by HPLC method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median concentration of ganciclovir in aqueous by HPLC-Mass spectrometry end of week 6</measure>
    <time_frame>6 weeks</time_frame>
    <description>Ganciclovir concentration in aqueous will be measured by HPLC-Mass spectrometry at the end of week 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy in clearing CMV viral load and resolution of anterior uveitis/endotheliitis following 6 weeks of treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical efficacy will be measured by resolution of anterior uveitis/ endotheliitis and aqueous tap negative for CMV realtime PCR at the end of week 6</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>2% guttae Ganciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% guttae Ganciclovir 5 times a day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% guttae ganciclovir</intervention_name>
    <description>2% guttae ganciclovir 5 times a day for 6 weeks</description>
    <arm_group_label>2% guttae Ganciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 21 and above&#xD;
&#xD;
          -  Patients who are diagnosed with anterior uveitis or endotheliitis with a positive&#xD;
             aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for Cytomegalovirus (CMV)&#xD;
&#xD;
          -  Patients with relapses and recurrent anterior segment disease that is PCR positive for&#xD;
             CMV in aqueous&#xD;
&#xD;
          -  Have not been on any form of (topical, local or systemic) ganciclovir therapy for the&#xD;
             past 1 month&#xD;
&#xD;
          -  Consent to undergo anterior chamber tap and give aqueous and tear samples for the&#xD;
             study&#xD;
&#xD;
          -  Able to undergo relevant tests (e.g. laser flare cell photometry)&#xD;
&#xD;
          -  Able to come for subsequent follow-up visits&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CMV anterior uveitis with associated retinitis&#xD;
&#xD;
          -  Other causes of hypertensive anterior uveitis / endotheliitis such as HSV, VZV&#xD;
             infection&#xD;
&#xD;
          -  Patients who have been on any form of (topical, local or systemic) ganciclovir therapy&#xD;
             for the past1 month.&#xD;
&#xD;
          -  Patients who are allergic to ganciclovir&#xD;
&#xD;
          -  Patients who will require systemic or intra-vitreal ganciclovir therapy&#xD;
&#xD;
          -  Immunocompromised patients&#xD;
&#xD;
          -  Positive for HIV, Hep B and Hep C&#xD;
&#xD;
          -  Not keen on participating in the study&#xD;
&#xD;
          -  Patients who are incapable, either by law or mental state, of giving consents in their&#xD;
             own right.&#xD;
&#xD;
          -  Patients who are either unable or unwilling to keep scheduled appointments and adhere&#xD;
             to the other aspects of the protocol&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  Any other specified reason as determined by the clinical investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SP Chee</last_name>
    <role>Study Chair</role>
    <affiliation>Singapre national eye centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samanthila Waduthantri</last_name>
    <phone>63228855</phone>
    <email>samanthila.waduthatri@snec.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samanthila Waduthantri</last_name>
      <email>samanthila.waduthantri@snec.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Singapore National Eye Centre</investigator_affiliation>
    <investigator_full_name>Soon Phaik Chee</investigator_full_name>
    <investigator_title>Senior Consultant &amp; HOD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

